US health care major Abbott Laboratories presented strong figures for the third quarter ending September 30, 2008, raising its net income by 50% compared to the same period of the year before. This was, in part, due to an 18% increase in revenue.
Sales were $7.5 billion versus $6.38 billion in the third quarter of 2007, whereas R&D expenses climbed only 6% to $680.4 million. Net profits jumped 51% to reach $1.08 billion, or $0.69 earnings per share, vs $717.0 million, or $0.46 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze